MOMA-341 / MOMA Therapeutics - LARVOL DELTA

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=132 | Not yet recruiting | Sponsor: MOMA Therapeutics

dMMR • Monotherapy • MSI-H • New P1 trial • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Microsatellite Instability • Oncology • Solid Tumor

Direct measurement of TA repeat expansions significantly outperforms MSI-H status as a predictor of sensitivity to the novel WRN inhibitor MOMA-341 (AACR 2025) - "However, these tumor responses could be converted to regressions when MOMA-341 was combined with chemotherapies such as irinotecan. This work demonstrates clearly that direct and specific measurement of the TA repeats that serve as a WRN helicase substrate is feasible, quantifiable and results in near perfect prediction of MOMA-341 anti-tumor activity in preclinical models, thereby successfully matching the relevant biology with pharmacologic response. Guided by this work, TA repeat expansions will be assessed in patient tumors within the upcoming Phase 1 clinical trial of MOMA-341 in dMMR/MSI-H tumors to better inform patient selection and the choice of single agent or combination dosing regimens."

MSI-H • Microsatellite Instability • Oncology • MSI • RECQL • WRN

MOMA Therapeutics to Present Multiple Posters at the American Association for Cancer Research Annual Meeting 2025 (Businesswire) - "MOMA Therapeutics...today announced three poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, being held April 25 – 30, 2025 in Chicago, IL."

Clinical data • Solid Tumor

MOMA Therapeutics Provides Corporate Update… (Businesswire) - "MOMA-313 is currently in a Phase 1a dose escalation study designed to evaluate its potential as monotherapy and in combination with olaparib, an approved, non-selective PARP inhibitor (NCT06545942). An initial readout of olaparib combination efficacy data is anticipated in mid-2026, with development of the proprietary combination with MOMA-989 to initiate in late 2026. The company remains on track to file an IND for MOMA-341 during the first quarter of 2025....The company plans to assess the potential of MOMA-341 as a treatment for patients with cancers demonstrating microsatellite instability (MSI-H). Following successful IND clearance, MOMA anticipates an initial readout of early single agent efficacy data in mid-2026."

IND • P1 data • Breast Cancer • Microsatellite Instability • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer